In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public offering nets $549mm for Seattle Genetics

Executive Summary

Seattle Genetics Inc. netted $549mm through a public offering of 8.2mm common shares (including the overallotment) at $70. The company develops and sells cancer therapies, and will use the proceeds to support ongoing commercialization activities in the US and Canada for Adcetris (brentuximab vedotin, indicated for various lymphomas); for the potential upcoming launch of enfortumab vedotin (in Phase II for bladder cancer); and for additional R&D and corporate needs.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies